Qualitative Concept – Page 72

Vyvgart Hytrulo, Argenx, FDA Approval, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Autoimmune Disease, Peripheral Nervous System Disorder

FDA Approves Adagrasib (Krazati) with Cetuximab for KRAS G12C-Mutated Colorectal Cancer

1 year ago talkbio0Tagged adagrasib, amgen, Approved, cetuximab, Colorectal Carcinoma, G12C, K-ras Oncogene, KRAZATI, Lumakras, Myers, squibb, United States Food and Drug Administration

Adagrasib, Krazati, Cetuximab, KRAS G12C, Colorectal Cancer, FDA Approval, Bristol Myers Squibb, Mirati Therapeutics, Amgen, Lumakras

Eli Lilly’s Zepbound Shows Promise in Treating Sleep Apnea, Seeks FDA Approval

1 year ago talkbio0Tagged Approved, Diabetes, Eli, Eli Lilly, Nordisk, United States Food and Drug Administration, Wegovy, Zepbound

Zepbound, Eli Lilly, sleep apnea, FDA approval, Novo Nordisk, Wegovy, weight loss, diabetes, pharmaceuticals

BMS’s KRAS Inhibitor Krazati Receives FDA Approval for Colorectal Cancer Treatment

1 year ago talkbio0Tagged adagrasib, Approved, cetuximab, Colorectal Carcinoma, Inhibitor, K-ras Oncogene, KRAZATI, Myers, squibb, United States Food and Drug Administration

Krazati, Bristol Myers Squibb, FDA approval, colorectal cancer, KRAS inhibitor, adagrasib, cetuximab

FDA Expands Approval of Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy to Include Older Boys and Non-Ambulatory Patients

1 year ago talkbio0Tagged Ambulatory - qualifier value, Approved, Duchenne, ELEVIDYS, gene therapy, Muscular Dystrophy, Unable to walk (finding), United States Food and Drug Administration

FDA, Sarepta, Duchenne Muscular Dystrophy, Gene Therapy, Elevidys, Ambulatory, Non-Ambulatory, Expanded Approval

AbbVie’s Skyrizi Secures Key FDA Approval for Ulcerative Colitis Treatment

1 year ago talkbio0Tagged AbbVie, Approved, Crohn 's disease, Inflammatory Bowel Diseases, Inhibitor, interleukin-23, Skyrizi, Ulcerative Colitis, United States Food and Drug Administration

Skyrizi, AbbVie, FDA approval, ulcerative colitis, inflammatory bowel disease, IL-23 inhibitor, Crohn’s disease

Amgen’s Blincyto Wins FDA Approval for Expanded Leukemia Use

1 year ago talkbio0Tagged Acute lymphocytic leukemia, amgen, Antibodies, Bispecific, Approved, Blincyto, leukemia, MRD, Neoplasm, Residual, United States Food and Drug Administration

Blincyto, Amgen, FDA Approval, Leukemia Treatment, Minimal Residual Disease (MRD), Acute Lymphoblastic Leukemia (ALL), Bispecific Antibody